Contineum Therapeutics, Inc. - Common stock (CTNM)
6.3300
-0.2600 (-3.95%)
Contineum Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative therapies aimed at addressing unmet medical needs, particularly in the fields of oncology and autoimmune diseases
The company leverages cutting-edge scientific research and advanced technology to create novel treatment options that enhance patient outcomes. By conducting rigorous clinical trials and collaborating with healthcare professionals, Contineum Therapeutics is committed to bringing transformative therapies to market that improve quality of life for patients suffering from complex medical conditions.
